Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F14%3A10291072" target="_blank" >RIV/00064165:_____/14:10291072 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/S1470-2045(14)70051-8" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(14)70051-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(14)70051-8" target="_blank" >10.1016/S1470-2045(14)70051-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study

Popis výsledku v původním jazyce

Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression- free survival (PFS), and overall survival in patients with metastatic melanoma that has a BRAF(V600) mutation. We assessed vemurafenib in patients with advanced metastatic melanoma with BRAF(V600) mutations who had few treatment options. Methods In an open-label, multicentre study, patients with untreated or previously treated melanoma and a BRAF(V600) mutation received oral vemurafenib 960 mg twice a day. The primary endpoint was safety. All analyses were done on the safety population, which included all patients who received at least one dose of vemurafenib. This report is the third interim analysis of this study.This study is registered with ClinicalTrials.gov, number NCT01307397.

Název v anglickém jazyce

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study

Popis výsledku anglicky

Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression- free survival (PFS), and overall survival in patients with metastatic melanoma that has a BRAF(V600) mutation. We assessed vemurafenib in patients with advanced metastatic melanoma with BRAF(V600) mutations who had few treatment options. Methods In an open-label, multicentre study, patients with untreated or previously treated melanoma and a BRAF(V600) mutation received oral vemurafenib 960 mg twice a day. The primary endpoint was safety. All analyses were done on the safety population, which included all patients who received at least one dose of vemurafenib. This report is the third interim analysis of this study.This study is registered with ClinicalTrials.gov, number NCT01307397.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FO - Dermatovenerologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet Oncology

ISSN

1470-2045

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

436-444

Kód UT WoS článku

000334301900041

EID výsledku v databázi Scopus

—